Thrivent Financial For Lutherans Aldeyra Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.77 - $4.22 $98,883 - $150,645	-35,698 Reduced 75.87%	11,356 $37,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $75,804 - $312,502	-51,568 Reduced 52.29%	47,054 $165,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $74,077 - $98,931	-12,124 Reduced 10.95%	98,622 $658,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $38,287 - $64,027	-5,385 Reduced 4.64%	110,746 $929,000
Q4 2022 Feb 08, 2023	BUY	$5.08 - $7.09 $497,281 - $694,040	97,890 Added 536.65%	116,131 $808,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $86,913 - $177,029	-22,872 Reduced 55.63%	18,241 $97,000
Q2 2022 Aug 16, 2022	BUY	$2.43 - $4.85 $99,904 - $199,398	41,113 New	41,113 $164,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.